cigna health-insurance lobbying pbm express-scripts healthcare
related: UnitedHealth Group - Optum Anthem - Elevance Health Blue Shield of California PBM Industry Bloc - OptumRx, CVS Caremark, Express Scripts PhRMA
Who They Are
The Cigna Group (formerly Cigna Corporation). A global health services company with $195 billion in annual revenue (2024), serving 180+ million customer relationships worldwide. Cigna merged with Express Scripts in 2018 for $67 billion, creating a vertically integrated health insurance and pharmacy benefit management (PBM) giant. The Express Scripts subsidiary is one of the three PBMs that collectively control 80% of the U.S. prescription drug market — extracting billions through rebate negotiations, formulary placement, and spread pricing that consumers never see.
Cigna PAC contributes $1.5-2 million per cycle and the company spends $8-10 million annually on lobbying. CEO David Cordani’s compensation exceeded $30 million in 2024.
What They Want
Cigna’s legislative priorities center on preventing PBM transparency regulation (which would expose the spread pricing and rebate structures that generate billions in opaque profit), opposing Medicare negotiation expansion, preventing public option or single-payer legislation, maintaining employer-based insurance as the dominant coverage model, and weakening surprise billing enforcement that limits out-of-network revenue.
The PBM fight is existential. Express Scripts’ business model depends on negotiating drug rebates with manufacturers and retaining a portion — a spread the consumer never sees. Federal and state legislation requiring PBM transparency would expose these profit margins and potentially destroy the intermediary model.
Who They Fund
Bipartisan distribution targeting Finance Committee members (Medicare/Medicaid jurisdiction), HELP Committee members (healthcare regulation), and Energy and Commerce Committee members (health insurance oversight). Cigna PAC also contributes to state-level candidates in states considering PBM regulation.
What They’ve Gotten
PBM Regulation Stalled: Despite bipartisan support for PBM transparency legislation, comprehensive federal reform has repeatedly stalled — preserving the opaque pricing structures that generate Express Scripts’ profits. State-level PBM bills have passed in some states but face industry legal challenges.
ACA Preservation Without Public Option: Cigna benefits from the ACA’s individual mandate and exchange structure (which creates captive customers) while opposing any expansion toward a public option that would compete with its commercial plans.
Express Scripts Merger Approval (2018): The $67 billion merger was approved by the DOJ without significant conditions, allowing Cigna to vertically integrate insurance and PBM operations — consolidating market power over both coverage decisions and drug pricing.
Contradiction
Cigna markets itself as a health company that helps people “improve their health, well-being, and peace of mind.” The company’s PBM subsidiary generates profits by inserting itself between patients and their medications, adding costs through rebate structures and spread pricing that inflate drug prices. The company whose mission is health profits from making healthcare more expensive.
Class Analysis
Cigna/Express Scripts represents the intermediary extraction layer in American healthcare. The company does not manufacture drugs, provide care, or treat patients — it inserts itself between those who do and those who need care, extracting profit at every transaction point. The PBM model is particularly extractive: manufacturers pay rebates to Express Scripts for formulary placement, pharmacies accept below-cost reimbursement, and consumers pay prices inflated by the rebate system they cannot see. Cigna’s lobbying operation protects this extraction model by preventing transparency regulation that would expose how much of every drug dollar is captured by the intermediary. CEO Cordani’s $30 million compensation is funded by the spread between what Cigna charges and what it pays — a spread borne by patients and employers.
Sources
- OpenSecrets: Cigna Group organizational profile (Tier 1)
- OpenSecrets: Cigna Group lobbying expenditures (Tier 1)
- FTC: PBM market concentration study (Tier 1)
- ProPublica: Why Do Americans Pay More for Prescription Drugs? (Tier 2)
- Ballotpedia: Cigna political spending (Tier 3)
content-readiness:: ready